The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Exclusion Criteria

• •1. Patients with Childs-Pugh B or C cirrhosis.
• •2. Female patients who are pregnant or breast-feeding.
• •3. Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.
• •4. Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study. This would include any uncontrolled or untreated viral infection such as HIV, HBV, HCV etc.
• •5. Subject is enrolled in a separate interventional clinical trial.
• •6. Active tuberculosis.
• •7. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
• •8. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
• •9. Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation.
• •10. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• •11. Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry.
• •12. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment.
• •13. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
• •18\. Active, untreated grade 2 or 3 varices. Patients with treated varices to the point that they are grade 1 or less will be allowed.
• •19\. Patients already on memantine for any reason prior to enrollment will be excluded.